GLPGFGalapagos N.V.

About Galapagos N.V. (GLPGF)

Galapagos N.V. (GLPGF) is a Biotechnology company headquartered in Mechelen, Belgium whose shares trade over-the-counter on the Pink tier.

Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti-infectives. Galapagos' approach is to develop drugs that stop or reverse a disease state using novel targets that are identified through a patent protected target discovery platform. Galapagos also provides access to its target and drug discovery platform through its services division, BioFocus and Argenta, which offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies.

GLPGF key facts

Ticker symbol

GLPGF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Mechelen, Belgium

Country of incorporation

BE

Year of incorporation

1999

Employees

830

Estimated market cap

$599.40M (as of Apr 11, 2025)

Shares outstanding

26,770,747

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Galapagos N.V. leadership

• Onno van de Stolpe — CEO
• Guillaume Jetten — CFO
• Elizabeth Goodwin — IR Manager

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with G